Advances and challenges in the treatment of esophageal cancer
Esophageal cancer (EC) is one of the most common cancers with high morbidity and mortality rates. EC includes two histological subtypes, namely esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC primarily occurs in East Asia, whereas EAC occurs in Western countries....
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-11-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383521000794 |
| _version_ | 1818345710142095360 |
|---|---|
| author | Shiming He Jian Xu Xiujun Liu Yongsu Zhen |
| author_facet | Shiming He Jian Xu Xiujun Liu Yongsu Zhen |
| author_sort | Shiming He |
| collection | DOAJ |
| description | Esophageal cancer (EC) is one of the most common cancers with high morbidity and mortality rates. EC includes two histological subtypes, namely esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC primarily occurs in East Asia, whereas EAC occurs in Western countries. The currently available treatment strategies for EC include surgery, chemotherapy, radiation therapy, molecular targeted therapy, and combinations thereof. However, the prognosis remains poor, and the overall five-year survival rate is very low. Therefore, achieving the goal of effective treatment remains challenging. In this review, we discuss the latest developments in chemotherapy and molecular targeted therapy for EC, and comprehensively analyze the application prospects and existing problems of immunotherapy. Collectively, this review aims to provide a better understanding of the currently available drugs through in-depth analysis, promote the development of new therapeutic agents, and eventually improve the treatment outcomes of patients with EC. |
| first_indexed | 2024-12-13T17:06:42Z |
| format | Article |
| id | doaj.art-9eca37b54fe44c4b85dd7c58d9a19ab3 |
| institution | Directory Open Access Journal |
| issn | 2211-3835 |
| language | English |
| last_indexed | 2024-12-13T17:06:42Z |
| publishDate | 2021-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-9eca37b54fe44c4b85dd7c58d9a19ab32022-12-21T23:37:39ZengElsevierActa Pharmaceutica Sinica B2211-38352021-11-01111133793392Advances and challenges in the treatment of esophageal cancerShiming He0Jian Xu1Xiujun Liu2Yongsu Zhen3Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, ChinaCorresponding authors.; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, ChinaCorresponding authors.; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, ChinaInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, ChinaEsophageal cancer (EC) is one of the most common cancers with high morbidity and mortality rates. EC includes two histological subtypes, namely esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC primarily occurs in East Asia, whereas EAC occurs in Western countries. The currently available treatment strategies for EC include surgery, chemotherapy, radiation therapy, molecular targeted therapy, and combinations thereof. However, the prognosis remains poor, and the overall five-year survival rate is very low. Therefore, achieving the goal of effective treatment remains challenging. In this review, we discuss the latest developments in chemotherapy and molecular targeted therapy for EC, and comprehensively analyze the application prospects and existing problems of immunotherapy. Collectively, this review aims to provide a better understanding of the currently available drugs through in-depth analysis, promote the development of new therapeutic agents, and eventually improve the treatment outcomes of patients with EC.http://www.sciencedirect.com/science/article/pii/S2211383521000794Drug combinationEsophageal adenocarcinomaEsophageal squamous cell carcinomaImmune therapyMolecular targeted therapy |
| spellingShingle | Shiming He Jian Xu Xiujun Liu Yongsu Zhen Advances and challenges in the treatment of esophageal cancer Acta Pharmaceutica Sinica B Drug combination Esophageal adenocarcinoma Esophageal squamous cell carcinoma Immune therapy Molecular targeted therapy |
| title | Advances and challenges in the treatment of esophageal cancer |
| title_full | Advances and challenges in the treatment of esophageal cancer |
| title_fullStr | Advances and challenges in the treatment of esophageal cancer |
| title_full_unstemmed | Advances and challenges in the treatment of esophageal cancer |
| title_short | Advances and challenges in the treatment of esophageal cancer |
| title_sort | advances and challenges in the treatment of esophageal cancer |
| topic | Drug combination Esophageal adenocarcinoma Esophageal squamous cell carcinoma Immune therapy Molecular targeted therapy |
| url | http://www.sciencedirect.com/science/article/pii/S2211383521000794 |
| work_keys_str_mv | AT shiminghe advancesandchallengesinthetreatmentofesophagealcancer AT jianxu advancesandchallengesinthetreatmentofesophagealcancer AT xiujunliu advancesandchallengesinthetreatmentofesophagealcancer AT yongsuzhen advancesandchallengesinthetreatmentofesophagealcancer |